Observational Study for Pediatric Rheumatologic Conditions
This observational study aims to develop a way to objectively measure pain and how well treatments work in children and young adults with Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), and Fibromyalgia. Currently, there is no specific intervention being tested. The goal is to find a "physiologic endpoint" (a measurable body response) that could help doctors choose the best treatment more precisely, rather than using a trial-and-error approach. This study is looking for about 90 participants between 5 and 21 years old who have a confirmed diagnosis of JIA, SLE, or Fibromyalgia. Success for this study means identifying a reliable way to characterize this endpoint, which will be measured over one year.
- Study design
- This is an observational study, meaning there is no randomization or blinding. It aims to enroll about 90 participants.
- What's involved
- Patients will be followed for a period of one year after enrollment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year after enrollment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Index Characterization1 Year
The primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations.